Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TIP Salvage Therapy in Germ Cell Tumors
NCT00002559Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jan 1994
- Primary completion
- Jan 2003
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of paclitaxel in Testicular Germ Cell Tumor (TGCT) and ovarian germ cell tumor (OGCT), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoints: Maximum Tolerated Dose, Toxicity and 1 more. Started Jan 1994; status: completed.
02
Drugs
paclitaxel
03
Conditions
Testicular Germ Cell Tumor (TGCT)ovarian germ cell tumor (OGCT)
Beyond the preview
Go deeper on NCT00002559.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002559.